Please login to the form below

Not currently logged in

Avillion names Allison Jeynes-Ellis CEO

Her career to date includes experience at ABPI, J&J, Roche, Wyeth, BMS and Novartis

Avillion, Allison Jeynes EllisAvillion has appointed the well-travelled and experienced Dr Allison Jeynes-Ellis as the company's new CEO.

Jeynes-Ellis has spent time at several major pharma companies in her 22-year career in the industry, including senior roles at Roche, Genentech Wyeth (now Pfizer), Bristol-Myers Squibb, Novartis, Nycomed and trade body the Association of the British Pharmaceutical Industry (ABPI).

These includes medical director positions and specific oncology positions and she also has consultancy experience at Johnson & Johnson and AstraZeneca.

Most recently Jeynes-Ellis was chief medical officer at Avillion, a UK-based company she co-founded in 2011 to focus on the co-development and financing of late-stage drug candidates.

She will now lead Avillion as it prepares to advance its first collaborative development agreement with Pfizer to conduct a global phase III clinical trial evaluating Bosulif (bosutinib) as a first-line treatment in chronic myelogenous leukaemia.

Kurt Wheeler, a non-executive director of Avillion, said: “We are confident that, under Allison's leadership, this agreement will be the first of several that Avillion signs over the coming years.”

19th February 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...